GlassScriptPhysician profile
Solomon C Huang
NPI 1184939381
$2,883.21
in general payments reported to CMS, 2019-2025
18 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $182 · 2021: $431 · 2022: $525 · 2023: $417 · 2024: $363 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.58 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $987.80 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $270.40 | 2022-2023 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $240.00 | 2019-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $229.60 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $204.71 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $182.99 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $116.83 | 2023-2024 | Farxiga, Saphnelo |
| Akebia Therapeutics INC | $110.67 | 2019-2025 | Auryxia, Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $95.80 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $91.73 | 2019-2024 | Velphoro |
| Novo Nordisk INC | $89.39 | 2023-2025 | Ozempic, Rybelsus |
| Amgen INC. | $75.72 | 2019-2023 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.79 | 2025 | Jardiance |
| Horizon Therapeutics Plc | $37.02 | 2022 | |
| Mallinckrodt Hospital Products INC. | $27.97 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $24.75 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $23.80 | 2021 | |
| Calliditas Therapeutics US INC. | $19.24 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solomon Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.